



Health Partners Plans

PHARMACY AND THERAPEUTICS COMMITTEE MEDICAID MEETING MINUTES February 23, 2023

Attendance: Onsite

Microsoft Teams Meeting

Yasmeen Alwethaiqi, Pharmacy Student Intern; Justin Bittner, Medical Director; Gary Bledsoe, Staff/Clinical Pharmacist; Connie Chan, Staff/Clinical Pharmacist; Jerry Crawford, Staff/Clinical Pharmacist; Dr. Neal Demp, Community Behavior Health; Danielle Dolores, Director of Pharmacy; George E. Downs, Dean Emeritus and Professor, St. Joseph's University; Demian Elder, Medical Director; Linda Evans, Magellan Health; Leah Finken, Clinical Programs Pharmacist; Sharon Ford, Staff/Clinical Pharmacist; Merleen Harris-Williams, Medical Director; Samantha Jackson, Clinical Pharmacist; Lawrence Jones, Director of Pharmacy, Phoenixville Hospital; Kaylei Koerwitz, Manager Pharmacy Operations and Clinical Programs; Dr. Tania Kolev, Medical Director; Kelvin Lu, Community Behavior Health; Brandi Mahler, Supervisor Pharmacy Technicians; Hannah McCaffrey, Manager Pharmacy Regulations & Implementation; Karleen Melody; Kateryna Olchowecky, Clinical Programs Pharmacist; Dr. Lou Parrott, Community Behavior Health; Maryana Prokopets, Staff/Clinical Pharmacist; Sanjiv Raj, Associate VP Customer Engagement; Sara Sadiq, Pharmacist; Julie Samuel, Clinical Programs Pharmacist; Heather Scheckner, Clinical Pharmacist, Jefferson Health; Robert Spencer, Staff/Clinical Pharmacist; Shelley Staffa, Clinical Pharmacist; Jessica Tran, Pharmacy Resident; Fallan Vaisberg, Formulary Pharmacist; Ramesh Vangala, Vice President of Pharmacy Operations; Jeanine Zubrzycki, Staff/Clinical Pharmacist; Diana Walczyk, Pharmacy Student, Community Behavior Health

Excused: Kay Chan, Manager Pharmacy Benefit Design and Audits; Edgar Chou, Jefferson Health; Oluwatoyin Fadeyibi, Community Behavior Health; Brian Swift, Enterprise Vice President/Chief Pharmacy Officer, Jefferson Health

Minutes taken by: Joana Iverson

I. Administrative Update

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING
<i>New P&T Committee Members</i>	<i>R. Vangala introduced new voting members</i>		<i>R. Vangala</i>	<i>Informational</i>
<i>Minutes Review/Approval</i>	<i>D. Dolores presented the minutes from the October 2022 meeting to the Committee for review.</i>	<i>The Committee approved the minutes from our last meeting as presented.</i>	<i>D. Dolores</i>	<i>Resolved</i>
<i>Expansion Update</i>	<i>D. Dolores presented stats regarding the Medicaid expansion that went live on September 1, 2022</i>		<i>D. Dolores R. Vangala</i>	<i>Informational</i>

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
2022 Review	<i>D. Dolores presented stats for 2022</i>		<i>D. Dolores R. Vangala</i>	<i>Informational</i>
Restriction Program Overview	<i>B. Mahler presented an overview of the Recipient Restriction Program</i>		<i>B. Mahler</i>	<i>Informational</i>
Medicaid/CHIP Formulary Review	<i>H. McCaffrey reviewed information regarding the Medicaid and CHIP formularies</i>		<i>H. McCaffrey</i>	<i>Informational</i>
Specialty Update	<i>K. Olchowecky provided an update on the specialty pharmacy network</i>		<i>K. Olchowecky</i>	<i>Informational</i>

II. Drug Formulary Review/Update

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
Prior Authorization Criteria – Review	<p><i>The Committee reviewed the Prior Authorization Criteria. The Committee approved as presented.</i></p> <ul style="list-style-type: none"> <i>Nuedexta</i> <i>Palynziq</i> <i>Sapropterin Dihydrochloride</i> 	<i>The Committee approved the criteria as presented. It will be sent to PARP for approval.</i>	<i>F. Vaisberg S. Jackson S. Jackson</i>	<i>Resolved</i>
Medical Policy Review	<p><i>The Committee reviewed the Medical Policy Review.. The Committee approved as presented.</i></p> <ul style="list-style-type: none"> <i>Spinraza</i> <i>Aduhelm, Leqembi</i> 	<i>The Committee approved the criteria as presented. It will be sent to PARP for approval.</i>	<i>J. Zubrzycki M. Smikovecus</i>	<i>Resolved</i>
Quantity Limit Additions	<p><i>The Committee reviewed the Quantity Limit Additions. The Committee approved as presented.</i></p> <ul style="list-style-type: none"> <i>Amphetamine-Dextroamphetamine ER 5mg, 10mg, 15mg, 20mg, 25mg, 30mg – 2/day</i> <i>Caplyta 10.5mg, 21 mg – 1/day</i> <i>Eletriptan – 9/30 days</i> <i>Lacosamide 10mg/ml solution – 40ml/day</i> <i>Levetiracetam Oral Soln 100 Mg/Ml – 40ml/day</i> <i>Levetiracetam Tab 250 Mg – 6/day</i> <i>Levetiracetam Tab 500 Mg – 6/day</i> <i>Nurtec ODT 75 mg tablet – 16/30 days</i> <i>Oxbryta 300 mg tab – 3/day</i> <i>Ozempic (2mg/dose) 8mg/3ml pen – 3/28 days</i> <i>Quetiapine fumarate tab 25 mg – 6/day</i> <i>Rabeprazole EC tab 20 mg – 2/day</i> <i>Repatha – 2ml/28 days</i> 	<i>The Committee approved as presented. The Quantity Limit Additions will be sent to PARP for approval.</i>	<i>F. Vaisberg</i>	<i>Resolved</i>

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
	<ul style="list-style-type: none"> • Repatha Pushtronex System – 7ml/28 days • Repatha Sureclick – 2ml/28 days • Wegovy 1.7 mg/0.75ml soln – 3ml/28 days • Wegovy 2.4 mg/0.75ml soln – 3ml/28 days 			
Quantity Limit Removals	<p>The Committee reviewed the Quantity Limit Removals. The Committee approved as presented.</p> <ul style="list-style-type: none"> • Acetazolamide 125mg, 250mg • Acetazolamide ER 500mg • Amoxicillin Cap 250mg, 500mg • Amoxicillin Chew Tab 125mg, 250mg • Amoxicillin Susp 125 mg/5ml, 200 mg/5ml, 250 mg/5ml, 400 mg/5ml • Amoxicillin Tab 500mg, 875mg • Amox/Clav Chew Tab 200-28.5mg, 400-5 mg • Amox/Clav Susp 200-28.5mg/5ml, 250-62.5mg/5ml, 400-57mg/5ml, 600-42.9mg/5ml • Amox/Clav 250-125mg, 500-125mg, 875-125 mg • Azithromycin Susp 100 mg/5ml, 200 mg/5ml • Azithromycin Tab 250mg, 500mg, 600mg • Benzonatate Cap 100mg, 200mg • Dicloxacillin Sodium Cap 250mg, 500mg • Fluticasone Propionate Oint 0.005% • Hydroxyzine Hcl 10mg/5ml Syrup • Hydroxyzine Pamoate 25mg, 50mg, 100mg • Isosorbide Mononitrate 10mg, 20mg • Minocycline 50mg, 75mg, 100mg • Penicillin V K Soln 125mg/5ml, 250mg/5ml • Penicillin V K Tab 250mg, 500mg • Rifampin 150mg, 300mg • Vancomycin 125mg, 250mg 	The Committee approved as presented. The Quantity Limit Removals will be sent to PARP for approval.	F. Vaisberg	Resolved
III. Specialty Drug Additions	<p>The Committee reviewed the Specialty Drug Additions. The Committee approved as presented.</p> <ul style="list-style-type: none"> • Fynetra 6mg/0.6mL • Imjudo 25mg/1.25mL • Imjudo 300mg/15mL • Lytgobi 4mg tab • Relyvrio Pak 3-1gm • Rolvedon injection 13.2mg/0.6mL • Tadliq suspension 20mg/5mL • Tecvayli injection 153mg/1.7mL 	The Committee approved as presented. The Specialty Drug Additions will be sent to PARP for approval.	F. Vaisberg	Resolved

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING
	<ul style="list-style-type: none"> • Tecvayli injection 30mg/3mL • Tziield Inj 2mg/ml • Udenyca Inj 6mg/.6ml 			
IV. New Drug Review	<p><i>J. Tran presented the New Drug Review list to the Committee. The following new products were reviewed and will be kept as non-formulary:</i></p> <ul style="list-style-type: none"> • Jaypirca (pirtobrutinib) Tablets • Orserdu (elacestrant) Tablets • Brenzavvy (bexagliflozin) Tablets • Rykindo (risperidone) for Extended-Release Injectable Suspension • Airsupra (albuterol and budesonide) Inhalation Aerosol • Leqembi (lecanemab-irmb) Injection • Briumvi (ublituximab-xiiy) Injection for IV Infusion • NexoBrid (anacaulase-bcdb) Topical Gel • Xenoview (xenon Xe 129 hyperpolarized) for Oral Inhalation • Sunlenca (lenacapavir) Injection and Tablets • Lunsumio (mosunetuzumab-axgb) Injection for IV Infusion • Olpruva (sodium phenylbutyrate) Oral Suspension • Adstiladrin (nadofaragene firadenovec-vncg) Suspension for Intravesical Use • Idacio (adalimumab-aacf) Injection for Subcutaneous use • Iyuzeh (latanoprost) Ophthalmic Solution • Krazati (adagrasib) Tablets • Rezlidhia (olutasidenib) Capsules • Rebyota (fecal microbiota, live-jslm) Suspension for Rectal Use • Hemgenix (etranacogene dezaparvovec-drlb) Suspension for IV Infusion • Tziield (teplizumab-mzwv) Injection for IV Infusion • Sezaby (phenobarbital sodium) Powder for Injection for IV infusion • Elahere (mirvetuximab soravtansine-gynx) Injection for IV Use • Tecvayli (teclistamab-cqyv) Injection for Subcutaneous Use • Imjudo (tremelimumab-actl) Injection for IV use 	<i>The Committee approved the New Drug Review as presented and recommended.</i>	<i>J. Tran</i>	<i>Resolved</i>

V. Adjournment

There being no further business to discuss, the meeting was adjourned. Next meeting is to be held May 2023.

A handwritten signature in blue ink that reads "Danielle Dolores".

3/6/2023

Danielle Dolores, Director of Pharmacy Services

Date